📋 Tender Overview
IntelGenx Corp. the Company or IntelGenx announced that it has entered into an amended and restated license agreement the Agreement granting Tetra Bio-Pharma Tetra a leader in cannabinoid-derived drug discovery and development additional exclusive worldwide rights including the right to manufacture IntelGenxs Adversa mucoadhesive delivery technology.The Adversa technology is designed to limit first-pass metabolism improve bioavailability enhance product stability and reduce gastro-intestinal exposure and side-effects. Tetra will use the Adversa technology to develop a THC-based mucoadhesive film containing its PPP-002 Dronabinol drug candidate for the treatment of chemotherapy-induced nausea and vomiting.Under the terms of the Agreement Tetra is purchasing the worldwide Adversa technology rights as it relates to its PPP-002 Dronabinol drug product candidate for three undisclosed milestone payments 45 to be paid on November 15 2020 45 to be paid on March 1 2021 and a final payment of 10 upon successful technology transfer. In addition Tetra will pay IntelGenx a low single digit royalty on future net sales of Dronabinol mucoadhesive tablets.This agreement reflects the many potential therapeutic benefits of our Adversa delivery technology said Dr. Horst G. Zerbe CEO of IntelGenx. In addition to being particularly well-suited for patients who have difficulty swallowing capsules a common and unfortunate side effect of chemotherapy Adversa offers comparable efficacy to capsules with a potentially superior side-effect profile.Steeve Nron Tetras Chief Commercial Officer commented We are looking forward to applying the Adversa technology to our PPP-002 drug candidate with the goal of providing better therapeutic value for both patients with chemotherapy-induced nausea and vomiting and their caregivers.
